Gastric cancer is the most common gastrointestinal cancer in China. The morbidity and mortality are extremely high and there are significant challenges in the treatment of gastric cancer. Recent studies have shown that the expressions of T lymphocyte subsets vary in the immune microenvironment of gastric cancer patients. T lymphocytes are not only the main effector cells of human cellular immunity, but also the important immunoregulatory cells. T lymphocytes not only reflect the state of the tumor microenvironment, but also closely relate with the prognosis of patients. T lymphocytes play a crucial guiding role in the clinical treatment. Currently, clinical trials related to immunological checkpoint inhibitors are still underway, among which PD-1/PD-L1 monoclonal antibody has been approved for the treatment of gastric cancer. The applications of tumor vaccines and adoptive cell therapies in gastric cancer are also being explored. How to screen patients suitable to immunotherapy, develop the best combination therapy and evaluate the effectiveness of immunotherapy need to be studied and solved.
胃癌是我国临床最常见的消化道恶性肿瘤，临床治疗存在很大的挑战。胃癌患者免疫微环境中存在T淋巴细胞亚群表达的变化。T淋巴细胞既是细胞免疫的主要效应细胞，又是人体重要的免疫调节细胞，不仅反映了肿瘤微环境的状态，与肿瘤患者预后有密切的关系，而且对肿瘤的临床治疗发挥至关重要的指导作用。目前，程序性细胞死亡因子1(PD－1)/程序性死亡分子配体1(PD－L1)单抗已获批用于胃癌的治疗，肿瘤疫苗、过继性细胞疗法在胃癌中的应用也在不断探索中。如何筛选免疫治疗患者、制定最佳联合治疗方案以及评估免疫治疗效果都是目前需要研究和解决的问题。.
Keywords: Cellular immunity; Gastric neoplasms; Research progress; T lymphocyte.